Medicine
Azulfidine 500 mg tablet
Azulfidine 500 mg tablet is a prescription medicine containing Sulfasalazine for oral use, marketed by Pfizer Laboratories, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 25° C (77° F), excursions permitted to 15–30° C (59–86° F).
Key facts
- Active ingredient (INN)
- Sulfasalazine
- Brand
- Azulfidine
- Strength
- 500 mg
- Dosage form
- Tablet
- Route
- Oral
- Packs
- 1 bottle
- Marketing authorisation holder
- Pfizer Laboratories
- Manufacturer
- Pfizer Laboratories
- Origin register
- US FDA, United States
- Storage
- Store at 25° C (77° F), excursions permitted to 15–30° C (59–86° F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- A07EC01 Sulfasalazine
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 20 June 1950
- Identifiers
- RxCUI 198232, 208437DailyMed set ID ddbe69f3-bd55-45f3-a64f-f60226c744c4NDC 0013-0101Application NDA007073
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 bottle in 1 carton / 100 tablet in 1 bottle | 0013-0101-10 | Pfizer Laboratories | 27 February 2020 |
| 1 bottle in 1 carton / 300 tablet in 1 bottle | 0013-0101-30 | Pfizer Laboratories | 27 February 2020 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 20 June 1950 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Sulfasalazine 500 mg tablet.
Other strengths and forms of Sulfasalazine
Clinical summary
Sulfasalazine is an aminosalicylate indicated to moderate ulcerative colitis, and as adjunctive therapy in severe ulcerative colitis, b) for the prolongation of the remission period between acute attacks of ulcerative colitis, among other approved uses. MedsAcross supplies Sulfasalazine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about SulfasalazineFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Sulfasalazine prescribing information (Mylan Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
Need Azulfidine 500 mg tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.